Antibody Production Market by Antibody Type, Process, End-User

KEY MARKET STATISTICS
Base Year [2023]	USD 17.97 billion
Estimated Year [2024]	USD 20.16 billion
Forecast Year [2030]	USD 40.77 billion
CAGR (%)	12.40%

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Production Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Production Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Production Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Bristol-Myers Squibb Company, Cell Signaling Technology, Inc., Eppendorf AG, F. Hoffmann-La Roche Ltd., Fibercell Systems Inc, GE HealthCare Technologies Inc., Genmab A/S, GenScript Biotech Corporation, Gilead Sciences, Inc., INTEGRA Biosciences AG, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pall Corporation, Pfizer Inc., ProteoGenix, Sanofi S.A., Sartorius AG, Teva Pharmaceutical Industries Ltd., The Antibody Company, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Antibody Production Market to forecast the revenues and analyze trends in each of the following sub-markets:

Antibody Type
- Monoclonal Antibodies
- Polyclonal Antibodies
Process
- Downstream Processing
  - Chromatography Resins
  - Chromatography Systems
- Filtration
  - Consumables & Accessories
  - Filtration Systms
- Upstream Processing
  - Bioreactors
  - Consumables
End-User
- Contract Research Organizations (CROs)
- Diagnostic Laboratories
- Pharmaceutical & Biotechnology Companies
- Research Institutes & Academic Centers
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Production Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Production Market?

3. What are the technology trends and regulatory frameworks in the Antibody Production Market?

4. What is the market share of the leading vendors in the Antibody Production Market?

5. Which modes and strategic moves are suitable for entering the Antibody Production Market?

Product Code: MRR-69324464D117

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Antibody Production Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of chronic diseases among population
  - 5.1.1.2. Growing demand for targeted therapies and personalized medicines
  - 5.1.1.3. Modernization of healthcare infrastructure and increase in healthcare expenditure
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with antibody production
- 5.1.3. Opportunities
  - 5.1.3.1. Robust research activities to introduce novel plant-made monoclonal antibody
  - 5.1.3.2. Emerging applications of bispecific antibodies in cancer immunotherapy
- 5.1.4. Challenges
  - 5.1.4.1. Stringent regulatory frameworks for antibody production
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Antibody Production Market, by Antibody Type

6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Polyclonal Antibodies

7. Antibody Production Market, by Process

7.1. Introduction
7.2. Downstream Processing
- 7.3.1. Chromatography Resins
- 7.3.2. Chromatography Systems
7.3. Filtration
- 7.4.1. Consumables & Accessories
- 7.4.2. Filtration Systms
7.4. Upstream Processing
- 7.5.1. Bioreactors
- 7.5.2. Consumables

8. Antibody Production Market, by End-User

8.1. Introduction
8.2. Contract Research Organizations (CROs)
8.3. Diagnostic Laboratories
8.4. Pharmaceutical & Biotechnology Companies
8.5. Research Institutes & Academic Centers

9. Americas Antibody Production Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Antibody Production Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Antibody Production Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. AbbVie Inc.
- 13.1.2. Amgen Inc.
- 13.1.3. AstraZeneca PLC
- 13.1.4. Biogen Inc.
- 13.1.5. Bristol-Myers Squibb Company
- 13.1.6. Cell Signaling Technology, Inc.
- 13.1.7. Eppendorf AG
- 13.1.8. F. Hoffmann-La Roche Ltd.
- 13.1.9. Fibercell Systems Inc
- 13.1.10. GE HealthCare Technologies Inc.
- 13.1.11. Genmab A/S
- 13.1.12. GenScript Biotech Corporation
- 13.1.13. Gilead Sciences, Inc.
- 13.1.14. INTEGRA Biosciences AG
- 13.1.15. Merck KGaA
- 13.1.16. Novartis AG
- 13.1.17. Novo Nordisk A/S
- 13.1.18. Pall Corporation
- 13.1.19. Pfizer Inc.
- 13.1.20. ProteoGenix
- 13.1.21. Sanofi S.A.
- 13.1.22. Sartorius AG
- 13.1.23. Teva Pharmaceutical Industries Ltd.
- 13.1.24. The Antibody Company
- 13.1.25. Thermo Fisher Scientific Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing